Polycystic Ovarian Syndrome (PCOS) is a health disorder characterized by an imbalance in a woman’s hormones. It is a disorder that disproportionately affects Black women, who are more likely to be at risk of cardiovascular diseases. The disorder cannot be cured and the medications for it often don’t do enough to help. Because of that, women are finding new ways to properly manage it.

In a recent Instagram post, Tim McGraw and Faith Hill’s daughter Gracie McGraw shared that she uses a low dose of Mounjaro to manage her PCOS diagnosis. She also shared that she previously tried Ozempic. Reports show that Black women who have been prescribed the medication, have also found it helpful in managing their diagnosis.

The Ozempic Craze

The Ozempic drug has been a point of conversation for months now. It is made from a compound called semaglutide. Ozempic helps the pancreas release insulin so as to move sugar from the blood into body tissues. Like Mounjaro, the drug was approved back in 2022 by FDA to treat type two diabetes.

The medication has, however, become the hottest weight-loss medication on the market. Many celebrities have been accused of taking the drug to fast-track their weight loss. A shortage resulted from the the drug’s popularity with those looking to shed pounds. In many cases patients diagnosed with type two diabetes have struggled to obtain it.

A Possible Breakthrough

Typically, PCOS patients are prescribed hormonal birth control, and anti-androgen medicines to manage their symptoms. Dr. Rekha Kumar is an endocrinologist and an expert in obesity and PCOS. In an interview with “Good Morning America,” Dr. Kumar said drugs like Ozempic and Mounjaro are a better alternative to traditional PCOS treatments because they address the main problem, insulin resistance.

“It’s not necessarily that we’re using the meds to treat PCOS, but the meds can be helpful for one of the symptoms of PCOS, which is the actual weight gain and hormonal drive to eat carbohydrate because of the insulin resistance,” Dr. Kumar said.

,